Changes In QTc Interval Duration Among Heroin Addicts On Methadone Treatment

1. World Health Organization. WHO model list of essential medicines, http://www.who.int/medicines/publications/essentialmedicines/en/index.html (2005).Search in Google Scholar

2. U.S. Food and Drug Administration. Methadone Hydrolcholoride. FDA alert [11/2006]: death, narcotic overdose, and serious cardiac arrhythmias. [updated 2008 August 23; cited 2006 Nov 29] Available from: http://www.fda.gov/cder/drug/advisory/methadone.htmSearch in Google Scholar

3. Cruciani RA. Methadone: to ECG or not to ECG...That is still the question. J Pain Symptom Manage. 2008 Nov;36(5):545-52.10.1016/j.jpainsymman.2007.11.003Search in Google Scholar

4. Kristensen, K, Christensen, C, The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 56, L45–L50 (1995).10.1016/0024-3205(94)00426-SSearch in Google Scholar

5. Gorman, A.L., Elliott.The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-Daspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 223, 5–8 (1997).10.1016/S0304-3940(97)13391-2Search in Google Scholar

6. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol. 2004;19:565–76.10.1002/hup.63015378662Search in Google Scholar

7. Eap, C.B., Buclin, T. & Baumann, P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet.41, 1153–1193 (2002).10.2165/00003088-200241140-0000312405865Search in Google Scholar

8. Gerber, J.G., Rhodes, R.J. & Gal, J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16, 36–44 (2004).10.1002/chir.1030314628297Search in Google Scholar

9. Crettol, S. et al. Methadone enantiomer plasma levels CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78, 593–604 (2005).Search in Google Scholar

10. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19:4–16.10.1111/j.1521-0391.2009.00005.x333428720132117Search in Google Scholar

11. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3: CD00220810.1002/14651858.CD00220812917925Search in Google Scholar

12. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.10.1001/jama.287.17.221511980521Search in Google Scholar

13. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7:353–70.Search in Google Scholar

14. Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. December 1997 [CPMP/986/96].Search in Google Scholar

15. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.10.1056/NEJMoa02214712736279Search in Google Scholar

16. Sanguinetti, M.C, Jiang, C, Curran, M.E. & Keating, M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299–307 (1995).10.1016/0092-8674(95)90340-2Search in Google Scholar

17. Katchman, A.N. et al. Influence of opioid agonists on cardiac humanether-a-go-go-related gene K+ currents. J. Pharmacol. Exp. Ther. 303,688–694 (2002). xxx. Kornick, C.A. et al. QTc interval prolongation associated with intravenous methadone. Pain 105, 499–506 (2003).10.1016/S0304-3959(03)00205-7Search in Google Scholar

18. Kornick, C.A. et al. QTc interval prolongation associated with intravenous methadone. Pain 105, 499–506 (2003).10.1016/S0304-3959(03)00205-7Search in Google Scholar

19. Wieneke H, Conrads H, Wolstein J, Breuckmann F, Gastpar M, Erbel R, Scherbaum N. Levo-alphaacetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial. Eur J Med Res. 2009 Jan 28;14(1):7-12.10.1186/2047-783X-14-1-7335220519258204Search in Google Scholar

20. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007 Dec 10;167(22):2469-75.10.1001/archinte.167.22.246918071169Search in Google Scholar

21. Krantz M. Heterogeneous Impact of Methadone on the QTc Interval: What Are the Practical Implications? J Addict Dis. 2008;27(4):5-9.10.1080/1055088080232431719042586Search in Google Scholar

22. Krantz M, Lowery C, Martell B, Gourevitch M and Arnsten J. Effects of Methadone on QT-Interval Dispersion. Pharmacotherapy 2005;25(11):1523–1529.10.1592/phco.2005.25.11.152316232014Search in Google Scholar

23. Martell B, MD, Arnsten J, Krantz M, and Gourevitch M. Impact of Methadone Treatment on Cardiac Repolarization and Conduction in Opioid Users. Am J Cardiol 2005;95:915–91810.1016/j.amjcard.2004.11.05515781034Search in Google Scholar

24. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2005;11(1):44-9.10.1159/00008141615608471Search in Google Scholar

25. Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev. 2011 Jul;30(4):388-96.10.1111/j.1465-3362.2010.00237.x21355918Search in Google Scholar

26. MHRA and Commission on Human Medicines. Risk of QT interval prolongation with methadone. 2006 May. Report No.: 31.Search in Google Scholar

27. Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol. 2011 Aug;25(4):503-10.10.1111/j.1472-8206.2010.00871.xSearch in Google Scholar

28. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009 Jun;104(6):993-9.10.1111/j.1360-0443.2009.02549.xSearch in Google Scholar

29. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment treatment (MMT) patients: a cross-sectional study. Addiction. 2007 Feb;102(2):289-300.10.1111/j.1360-0443.2006.01668.xSearch in Google Scholar

30. Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, Besson J, Croquette-Krokar M, Carrupt PA, Abriel H. Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers. Clin Pharmacol Ther. 2007 May; 81(5):719-28.10.1038/sj.clpt.6100120Search in Google Scholar

31. Routhier DD, Katz KD, Brooks DE. QTc prolongation and torsades de pointes associated with methadone therapy. J Emerg Med. 2007 Apr;32(3):275-8. Epub 2007 Feb 2.10.1016/j.jemermed.2006.07.027Search in Google Scholar

32. Lamont P, Hunt SC. A twist on torsade: a prolonged QT interval on methadone. J Gen Intern Med. 2006 Nov;21(11):C9-C12.10.1111/j.1525-1497.2006.00588.xSearch in Google Scholar

33. Sanchez Hernandez AM, Atienza Fernandez F, Arenal Maiz A, Gonzalez Torrecilla E, Puchol Calderon A, Almendral Garrote J. Torsades de pointes during methadone treatment. Rev Esp Cardiol. 2005 Oct;58(10):1230-2.10.1016/S1885-5857(06)60403-9Search in Google Scholar

34. U.S. Food and Drug Administration. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland; 2005.Search in Google Scholar

35. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004 Mar 4;350(10):1013-22.10.1056/NEJMra03242614999113Search in Google Scholar

36. Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H. Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. Drug Alcohol Depend. 2010 Dec 1;112(3):216-9. doi: 10.1016/j.drugalcdep.2010.06.015. Epub 2010 Aug 10.10.1016/j.drugalcdep.2010.06.01520702049Search in Google Scholar